Irsenontrine
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases[1][2][3].
Product Specifications
CAS Number
1429509-82-9
Product Name Alternative
E2027
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/irsenontrine.html
Purity
99.91
Solubility
DMSO : 12.5 mg/mL (warming; heat to 60°C)
Smiles
O=C1C2=C(N([C@@]3([H])CCOC3)N=C2)C4=CC=C(C5=C(C)C=NC(OC)=C5C)C=C4N1
Molecular Formula
C22H22N4O3
Molecular Weight
390.44
References & Citations
[1]Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1|[2]Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36 (4) :309-319.|[3]Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE9
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
